BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17363512)

  • 21. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
    Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
    J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
    Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
    J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of HSP90 molecular chaperones: moving into the clinic.
    Garcia-Carbonero R; Carnero A; Paz-Ares L
    Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis modulators as cancer therapeutics.
    Penn LZ
    Curr Opin Investig Drugs; 2001 May; 2(5):684-92. PubMed ID: 11569948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highlights in experimental therapeutics.
    Burger AM
    Cancer Lett; 2007 Jan; 245(1-2):11-21. PubMed ID: 16647200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
    Gray PJ; Stevenson MA; Calderwood SK
    Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat shock protein 90 acts as a molecular chaperone in late-phase activation of extracellular signal-regulated kinase 1/2 stimulated by oxidative stress in vascular smooth muscle cells.
    Liu DH; Yuan HY; Cao CY; Gao ZP; Zhu BY; Huang HL; Liao DF
    Acta Pharmacol Sin; 2007 Dec; 28(12):1907-13. PubMed ID: 18031603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein chaperones as anticancer therapy targets.
    Sausville E
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
    Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells.
    Meyer PN; Roychowdhury S; Kini AR; Alkan S
    Leuk Res; 2008 Jan; 32(1):143-9. PubMed ID: 17617451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.
    Nieto-Miguel T; Gajate C; González-Camacho F; Mollinedo F
    Oncogene; 2008 Mar; 27(12):1779-87. PubMed ID: 17891170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines.
    Håvik B; Bramham CR
    Oncol Rep; 2007 Jun; 17(6):1501-10. PubMed ID: 17487411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Functions of Hsp90, a major stress protein, as a molecular chaperone].
    Kimura Y; Yahara I
    Tanpakushitsu Kakusan Koso; 1996 Jun; 41(7):883-7. PubMed ID: 8966217
    [No Abstract]   [Full Text] [Related]  

  • 39. 5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone.
    Cikotiene I; Kazlauskas E; Matuliene J; Michailoviene V; Torresan J; Jachno J; Matulis D
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1089-92. PubMed ID: 19168355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.